Prostate Cancer Blood Test, APIFINY, Being Promoted in US by Aeterna Zentaris

Prostate Cancer Blood Test,  APIFINY, Being Promoted in US by Aeterna Zentaris
Aeterna Zentaris Inc. announced it has begun promoting  APIFINY, the only non-PSA blood test for the evaluation of prostate cancer risk, in the U.S. under a co-marketing agreement with Armune BioScience, Inc. Under the agreement, Zentaris will promote APIFINY to designated medical professionals in 20 American territories, and receive a commission for each test that results from its

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *